# Patrick Soon-Shiong

> Patrick Soon-Shiong is a Series E investor at NantCapital backing Health Care and Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [NantCapital](https://shizune.co/investors/profile/nantcapital)
- Location: Port Shepstone, South Africa
- Total investments: 4
- Last investment: Feb 2026
- Lead investor: 100%
- Last updated: Aug 2026
- Website: https://x.com/ShiongSoon
- Facebook: https://www.facebook.com/profile.php?id=100063607862406

Patrick Soon-Shiong is a Series E investor at NantCapital in Port Shepstone focused on Health Care and Medical. Patrick Soon-Shiong is the Founder of NantBio. He attended the University of Witwatersrand.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 50% |
| Medical | 1 | 25% |
| Therapeutics | 1 | 25% |
| Biotechnology | 1 | 25% |
| Manufacturing | 1 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series E | 1 | 25% |
| Post-IPO Debt | 1 | 25% |
| Post-IPO Equity | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SHINE Technologies | SHINE Medical Technologies, Inc. manufactures and supplies medical tracers and cancer treatment elements. The company offers Molybdenum-99, a light-emitting element that is administered to patients for the purpose of diagnosing and staging cancer and heart diseases. It also provides Iodine-131 that is used to treat thyroid cancer and variousabnormal thyroid conditions, including hyperthyroidism, as well as to diagnose liver function, renal blood flow, and urinary tract obstruction.The company was founded in 2010 and is headquartered in Janesville, Wisconsin. | $240M | Series E | Feb 26, 2026 |  |
| ImmunityBio | NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks. | $50M | Post-IPO Debt | Dec 12, 2022 |  |
| ImmunityBio | NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks. | $107M | Post-IPO Equity | Dec 12, 2022 |  |
| ImmunityBio | NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks. |  | Post-IPO Equity |  |  |

4 of 4 investments shown.

## Co-investors
- [Deerfield](https://shizune.co/investors/profile/deerfield) — VC Fund, 1 deal together
- [Fidelity](https://shizune.co/investors/profile/fidelity-investments) — VC Fund, 1 deal together
- [Oaktree Capital Management](https://shizune.co/investors/profile/oaktree-capital-management) — VC Fund, 1 deal together
- [Pelican Energy Partners](https://shizune.co/investors/profile/pelican-energy-partners-2) — VC Fund, 1 deal together
- [Sumitomo Corporation of America](https://shizune.co/investors/profile/sumitomo-corporation-of-america) — VC Fund, 1 deal together

## About NantCapital

VC Fund · Culver City, United States

They are fast entering a new age. A worldwide shift as significant as any in history. They call it The Cognitive Age. Combining the collective promise of science, technology and communication. And then making it accessible to all people.

2 contacts available at NantCapital.

| Name | Title | Profile |
| --- | --- | --- |
| Patrick Soon-Shiong | Founder | https://shizune.co/investors/profile/patrick-soon-shiong-f565 |
| Richard Binier | CEO | https://shizune.co/investors/profile/richard-binier |

## Similar investors

### Similar stage
- [Krungsri Finnovate](https://shizune.co/investors/profile/krungsri-finnovate) — VC Fund
- [Munich Venture Partners](https://shizune.co/investors/profile/munich-venture-partners) — VC Fund
- [yet2Ventures](https://shizune.co/investors/profile/yet2ventures) — VC Fund

## FAQ

### What does Patrick Soon-Shiong invest in?

Patrick Soon-Shiong invests primarily in Health Care, Medical and Therapeutics startups, most often at Series E and Post-IPO Debt stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Patrick Soon-Shiong last invest?

The most recent investment recorded for Patrick Soon-Shiong closed in Feb 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co